$9.43
5.47% yesterday
Nasdaq, May 20, 09:51 pm CET
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Septerna Stock price

$9.42
+3.55 60.48% 1M
-13.08 58.13% 6M
-13.48 58.86% YTD
-8.58 47.67% 1Y
-8.58 47.67% 3Y
-8.58 47.67% 5Y
-8.58 47.67% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.55 5.52%
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Key metrics

Market capitalization $419.74m
Enterprise Value $108.76m
EV/Sales (TTM) EV/Sales 178.30
P/S ratio (TTM) P/S ratio 688.10
P/B ratio (TTM) P/B ratio 1.05
Revenue (TTM) Revenue $610.00k
Cash position $336.01m
EPS (TTM) EPS $-1.43
P/E forward negative
P/S forward 3.05
EV/Sales forward 0.79
Short interest 12.40%
Show more

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Septerna forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Septerna forecast:

Buy
75%
Hold
25%

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.61 0.61
-
100%
- Direct Costs 1.15 1.15
-
189%
0.61 0.61
-
100%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT - -
-
-
Net Profit -63 -63
-
-10,274%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Positive
Seeking Alpha
4 days ago
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require ...
Positive
Seeking Alpha
4 days ago
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending ...
Neutral
GlobeNewsWire
5 days ago
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Employees 75
Website www.septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today